Skip to content
MedsAcross

Medicine

Abiraterone 500 mg tablet

Abiraterone · Oral
Available on requestPrescription onlyUS FDAGeneric name

Abiraterone 500 mg tablet is a generic prescription medicine for oral use, made by 15 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20°C to 25°C (68°F to 77°F), excursions permitted in the range from…

Key facts

Active ingredient (INN)
Abiraterone
Brand
Sold under the generic name
Strength
500 mg
Dosage form
Tablet
Route
Oral
Packs
6 blister pack, 60 tablets, 500 tablets and 14 more
Manufacturers
Dr. Reddy's LaboratoriesIndiaNovadoz PharmaceuticalsIndiaGlenmark PharmaceuticalsIndiaAmneal PharmaceuticalsAmneal Pharmaceuticals NYApotexAvKAREBluePoint LaboratoriesBryant Ranch PrepackFlorida Pharmaceutical Products
Origin register
US FDA, United States
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted in the range from 15°C to 30°C (59°F to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L02BX03 Abiraterone
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
7 January 2019
Identifiers
RxCUI 1918042, 1100075DailyMed set ID 68121a71-5024-4f9e-bd9c-2d412f6a6355, f308b463-27e4-422a-95a2-ecbbf95eee20, c1200e4e-c4f7-9067-e053-2a95a90af509 +12NDC 71921-177, 82293-002, 42291-073 +12Application ANDA215086, ANDA215947, ANDA208327 +5

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
6 blister pack in 1 carton / 10 tablet in 1 blister pack43598-468-38Dr. Reddy's LaboratoriesIndia11 September 2023
60 tablet in 1 bottle43598-468-60Dr. Reddy's LaboratoriesIndia11 September 2023
60 tablet in 1 bottle68462-882-60Glenmark PharmaceuticalsIndia19 May 2022
500 tablet, film coated in 1 bottle72205-285-05Novadoz PharmaceuticalsIndia24 May 2024
60 tablet, film coated in 1 bottle72205-285-60Novadoz PharmaceuticalsIndia24 May 2024
60 tablet in 1 bottle60219-1754-6Amneal Pharmaceuticals28 April 2023
60 tablet in 1 bottle69238-1754-6Amneal Pharmaceuticals NY7 January 2019
60 tablet, film coated in 1 bottle60505-4764-6Apotex16 July 2021
60 tablet, film coated in 1 bottle71921-177-06Florida Pharmaceutical Products10 April 2023
60 tablet, film coated in 1 bottle, plastic0378-6921-91Mylan Pharmaceuticals14 December 2020
60 tablet, film coated in 1 bottle, plastic82293-002-10Novugen Pharma5 January 2022
60 tablet in 1 bottle42291-073-60AvKARE29 April 2021
60 tablet in 1 bottle68001-673-06BluePoint Laboratories16 October 2025
60 tablet, film coated in 1 bottle, plastic72162-2151-6Bryant Ranch Prepack7 December 2023
60 tablet, film coated in 1 bottle, plastic51407-989-60Golden State Medical Supply17 June 2026
60 tablet in 1 bottle72603-111-01Northstar RX19 May 2022
60 tablet, film coated in 1 bottle82009-140-60Quallent Pharmaceuticals Health16 July 2024

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 28 April 2011Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Abiraterone 500 mg tablet.

Compare 1

Other strengths and forms of Abiraterone

Clinical summary

Abiraterone is a cytochrome P450 17A1 inhibitor. It is available as tablets for oral use. MedsAcross supplies Abiraterone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Abiraterone

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Abiraterone 500 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.